New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.1 mg/ml equivalent to 0.089 mg desmopressin free base - nasal spray solution - 0.1 mg/ml - active: desmopressin acetate trihydrate 0.1 mg/ml equivalent to 0.089 mg desmopressin free base excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate dihydrate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 100 µg/ml equivalent to 8 9µg/ml desmopressin free base - nasal drops - 100 mcg/ml - active: desmopressin acetate trihydrate 100 µg/ml equivalent to 8 9µg/ml desmopressin free base excipient: chlorobutanol hemihydrate hydrochloric acid purified water sodium chloride - minirin nasal drops solution is indicated for the treatment of central diabetes insipidus and for establishing renal concentration capacity testing.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.1mg equivalent to 0.089 mg free base - tablet - 0.1 mg - active: desmopressin acetate trihydrate 0.1mg equivalent to 0.089 mg free base excipient: ethanol lactose monohydrate magnesium stearate potato starch povidone purified water

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.1mg equivalent to 0.089 mg free base - tablet - 0.1 mg - active: desmopressin acetate trihydrate 0.1mg equivalent to 0.089 mg free base excipient: lactose monohydrate magnesium stearate potato starch povidone

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.1mg equivalent to 0.089 mg desmopressin free base - nasal spray solution - 10 mcg/dose - active: desmopressin acetate trihydrate 0.1mg equivalent to 0.089 mg desmopressin free base excipient: benzalkonium chloride citric acid monohydrate dibasic sodium phosphate dihydrate sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.2mg equivalent to 0.178 mg free base - tablet - 0.2 mg - active: desmopressin acetate trihydrate 0.2mg equivalent to 0.178 mg free base excipient: ethanol lactose monohydrate magnesium stearate potato starch povidone purified water - the treatment of primary nocturnal enuresis in patients (from 5 years of age) with normal ability to concentrate urine.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - desmopressin acetate trihydrate 0.2mg equivalent to 0.178 mg free base - tablet - 0.2 mg - active: desmopressin acetate trihydrate 0.2mg equivalent to 0.178 mg free base excipient: lactose monohydrate magnesium stearate potato starch povidone

United States - English - NLM (National Library of Medicine)

amring pharmaceuticals inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 4 ug in 1 ml - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of s

United States - English - NLM (National Library of Medicine)

american health packaging - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.1 mg - desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. desmopressin acetate tablets are ineffective for the treatment of nephrogenic diabetes insipidus. patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. desmopressin acetate tablets may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablet

United States - English - NLM (National Library of Medicine)

apotex corp. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate 0.1 mg - desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablets. desmopressin a